Watch ICCC. Know when insiders buy.
One email the day a filing lands. Free.
ICCC
IMMUCELL CORP /DE/
9.98
+0.37 +3.85%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $90.6MP/E 142.6DIV YIELD —FCF YIELD 4.65%REV TTM $30.7M +8.5%NET INCOME $787K −55.3%NET CASH $557K52W 4.56 – 11.72SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $7.2M | +11.5% | 33.9% | $1.9M | $1.8M | +265.6% | 0.20 | $3M | $734K | $2.3M | Aug 13 |
| Q1 2026 · Mar 31 | $10.4M | +28.4% | 45.0% | $2M | $1.9M | +34.2% | 0.21 | $3.6M | $177K | $3.4M | May 14 |
| Q4 2025 · Dec 31derived | $7.6M | −1.6% | 38.2% | −$58K | −$2.8M | −653.7% | -0.32 | $483K | $172K | $310K | Mar 30 |
| Q3 2025 · Sep 30 | $5.5M | −8.4% | 42.9% | $20K | −$140K | — | -0.02 | −$1.2M | $594K | −$1.8M | Nov 13 |
| Q2 2025 · Jun 30 | $6.4M | +17.8% | 43.7% | $570K | $502K | — | 0.06 | $1.6M | $155K | $1.4M | Aug 13 |
| Q1 2025 · Mar 31 | $8.1M | +11.2% | 41.6% | $1.1M | $1.4M | — | 0.16 | $1.6M | $329K | $1.2M | May 14 |
| Q4 2024 · Dec 31derived | $7.8M | +52.1% | 36.5% | $621K | $515K | — | 0.08 | −$3K | $196K | −$199K | Mar 30 |
| Q3 2024 · Sep 30 | $6M | +11.4% | 26.3% | −$575K | −$702K | — | -0.09 | −$639K | $88K | −$728K | Nov 13 |
| Q2 2024 · Jun 30 | $5.5M | — | 22.5% | −$1.4M | −$1.5M | — | -0.20 | $582K | $111K | $471K | Aug 14 |
| Q1 2024 · Mar 31 | $7.3M | — | 31.6% | −$300K | −$438K | — | -0.06 | $419K | $70K | $348K | May 14 |
| Q4 2023 · Dec 31derived | $5.1M | — | 0.0% | $0 | −$1.1M | — | -0.15 | −$723K | $81K | −$804K | Mar 28 |
| Q3 2023 · Sep 30 | $5.4M | — | 23.5% | −$1.2M | −$940K | — | -0.12 | −$508K | $421K | −$928K | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $27.6M | 41.4% | $1.6M | −$1M | -3.8% | -0.12 | $2.5M | $1.3M | $1.2M | — | — |
| FY2024 · to Dec 31 | $26.5M | 30.0% | −$1.6M | −$2.2M | -8.1% | -0.26 | $358K | $466K | −$108K | — | — |
| FY2023 · to Dec 31 | $17.5M | 22.1% | −$5.7M | −$5.8M | -33.1% | -0.75 | −$4.7M | $1.9M | −$6.6M | — | — |
| FY2022 · to Dec 31 | $18.6M | 41.2% | −$2.3M | −$2.5M | -13.4% | -0.32 | −$1.5M | $4M | −$5.5M | — | — |
| FY2021 · to Dec 31 | $19.2M | 45.0% | $257K | −$78K | -0.4% | -0.01 | $954K | $2.6M | −$1.7M | — | — |
| FY2020 · to Dec 31 | $15.3M | 44.7% | −$1.4M | −$1M | -6.7% | -0.14 | $1.3M | $4.1M | −$2.8M | — | — |
Every number comes from IMMUCELL CORP /DE/'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.